Business Wire National BioTech News
- Rapid Dose Therapeutics Reports Quarterly Financial Results for First Three Quarters of the 2023 Fiscal Year
- Rapid Dose Therapeutics Reports Fiscal Year 2022 Financial Results
- Wellbeing Announces Delay in Filing Its Financial Statements and Management Cease Trade Order
- Enveric Biosciences to Present at the BIO CEO & Investor Conference
- Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004
- Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection)
- Eclipsebio Launches eRibo™ for Improved Methods to Profile Protein Translation; Technology Details Will Be Presented at Keystone Symposia
- Ondine’s nasal photodisinfection therapy (APDT) improves short-term and long-term immune response while significantly reducing SARS-CoV-2 infectivity
- Toronto Airport Authority Partners with Kraken Sense, a Leading Canadian Tech Company, as Part of Study to Combat COVID-19
- Recruiting Underway in FSD Pharma’s Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
RECENT TWEETS
Incredible news for Life Sciences in Atlantic Can! @EmerGenceBio has received $3.18M to get their next business plan off the ground which they expect will support 55 biosciences businesses annually! https://t.co/ePSLSfKDvd
